Paradigm Biocapital Advisors LP Raises Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Paradigm Biocapital Advisors LP increased its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 3.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,236,346 shares of the company's stock after acquiring an additional 150,000 shares during the quarter. Y-mAbs Therapeutics comprises 1.2% of Paradigm Biocapital Advisors LP's holdings, making the stock its 22nd biggest position. Paradigm Biocapital Advisors LP owned 9.46% of Y-mAbs Therapeutics worth $33,171,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of YMAB. KLP Kapitalforvaltning AS acquired a new position in Y-mAbs Therapeutics during the 4th quarter valued at approximately $46,000. Wells Fargo & Company MN increased its stake in shares of Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after acquiring an additional 6,131 shares during the period. SG Americas Securities LLC increased its stake in shares of Y-mAbs Therapeutics by 30.7% in the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after acquiring an additional 4,163 shares during the period. XTX Topco Ltd increased its stake in shares of Y-mAbs Therapeutics by 83.8% in the fourth quarter. XTX Topco Ltd now owns 20,768 shares of the company's stock worth $163,000 after acquiring an additional 9,468 shares during the period. Finally, Principal Financial Group Inc. increased its stake in shares of Y-mAbs Therapeutics by 9.4% in the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock worth $174,000 after acquiring an additional 1,903 shares during the period. Institutional investors and hedge funds own 70.85% of the company's stock.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now owns 202,721 shares in the company, valued at approximately $1,060,230.83. The trade was a 5.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 22.50% of the company's stock.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB traded up $0.13 during mid-day trading on Monday, reaching $4.23. The company's stock had a trading volume of 106,897 shares, compared to its average volume of 363,078. The stock has a 50-day moving average of $4.47 and a two-hundred day moving average of $7.00. The stock has a market capitalization of $191.55 million, a P/E ratio of -7.83 and a beta of 0.53. Y-mAbs Therapeutics, Inc. has a 1-year low of $3.55 and a 1-year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $20.90 million during the quarter, compared to analysts' expectations of $19.97 million. Analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on YMAB. HC Wainwright cut their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Monday. Morgan Stanley cut their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 5th. Wedbush reissued an "outperform" rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Bank of America downgraded shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a report on Tuesday, April 22nd. Finally, Oppenheimer lowered their price target on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.60.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.